Related Experiment Video

Updated: Dec 26, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

miR-524-5p inhibits angiogenesis through targeting WNK1 in colon cancer cells

Xiang Li1, Zitao Li2, Ye Zhu3

  • 1Department of Ultrasonic Diagnosis, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.

American Journal of Physiology. Gastrointestinal and Liver Physiology
|March 17, 2020
PubMed

Insights

MicroRNA-524-5p inhibits colon cancer growth by targeting with-no-lysine kinase 1 (WNK1), suppressing angiogenesis. This finding offers a potential therapeutic strategy for colon cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNA (miRNA) dysregulation is implicated in various cancers, including colon cancer.
  • MiRNA-524-5p exhibits anticancer properties, but its role in colon cancer angiogenesis is underexplored.

Purpose of the Study:

  • To investigate the role of the miRNA-524-5p/with-no-lysine kinase 1 (WNK1) axis in colon cancer angiogenesis.
  • To elucidate the underlying mechanisms of miRNA-524-5p's action in colon cancer cells.

Main Methods:

  • Utilized human colon cancer cell lines (HT-29, COLO205) and a murine tumor model.
  • Manipulated miRNA-524-5p and WNK1 expression levels.
  • Assessed cell proliferation, cell cycle, vascular endothelial growth factor (VEGF) production, and angiogenesis.

Main Results:

  • MiRNA-524-5p expression varied between colon cancer cell lines.
  • Increased miRNA-524-5p suppressed proliferation, induced cell cycle arrest, reduced VEGF, and inhibited angiogenesis in HT-29 cells.
  • WNK1 silencing demonstrated anti-angiogenic effects; miRNA-524-5p deficiency-induced angiogenesis was counteracted by WNK1 silencing in COLO205 cells.
  • In vivo, miRNA-524-5p agomir treatment reduced tumor growth and WNK1 expression.

Conclusions:

  • MiRNA-524-5p inhibits colon cancer angiogenesis by targeting WNK1.
  • The miRNA-524-5p/WNK1 pathway represents a potential therapeutic target for colon cancer.
Keywords:
WNK1angiogenesiscolon cancermiRNA-524-5p

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.2K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.2K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K